Surrozen Inc（SRZN）资讯与事件

$25.320

+0.182 (+0.72%)收盘时

SRZN 资讯

8.510-20Newsfilter

Surrozen Closes $95.1 Million Financing to Advance Ophthalmology Pipeline

2.009-25stocktwits

Biotech Company Performance Analysis

9.009-08Newsfilter

Surrozen Submits IND Application for SZN-8141 to Treat Diabetic Macular Edema

9.505-07seekingalpha

Surrozen Reports Strong Q1 Revenue Growth Despite Losses

9.503-23seekingalpha

Surrozen Reports Increased Losses in FY Results

4.503-23moomoo

Surrozen Reports FY EPS of USD -32.37

5.002-23Newsfilter

Surrozen Grants Stock Options to Attract New Employee

9.508-08NASDAQ.COM

Surrozen Reports Q2 Profit on Gains

9.508-08Newsfilter

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

9.005-14Newsfilter

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

查看更多资讯

SRZN 事件

10/2 08:30

Surrozen's SZN-8141 IND Application Approved, Expected to Raise $95.1M

Surrozen announced its Investigational New Drug, IND, application for SZN-8141 has become effective, enabling the Company to advance the program into clinical development. SZN-8141 is a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody being developed as an intravitreal injection for the treatment of diabetic macular edema, DME. The FDA clearance of the SZN-8141 IND satisfies the second closing milestone under Surrozen's March 2025 two-tranche private placement. Subject to the terms and conditions of the securities purchase agreement, the second closing is expected to provide approximately $95.1M in gross proceeds to Surrozen, before deducting placement agent fees and other expenses. The second closing is expected to occur on or about October 20, 2026, subject to satisfaction of the applicable closing conditions.

9/8 09:30

Surrozen Submits New Drug Application for SZN-8141 to FDA

Surrozen announced the submission of an investigational new drug application to the FDA seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor antagonist antibody, for the treatment of diabetic macular edema.

5/6 16:50

Surrozen Q1 Revenue Hits $5M, Exceeds Consensus

Reports Q1 revenue $5M, consensus $4M. The company said, "Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen's pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs."

3/23 17:30

Surrozen Files $200M Mixed Securities Shelf

Surrozen files $200M mixed securities shelf

11/7 16:18

Surrozen appoints Andrew Maleki as Chief Financial Officer

Andrew Maleki has joined the Surrozen management team as CFO. Maleki brings more than a decade of experience in the biotech industry spanning corporate strategy, business development and operational leadership, including playing a key role in raising over $500M in capital. Most recently, he led corporate development and program leadership at Lassen Therapeutics, where he helped shape portfolio strategy and business development efforts.

查看更多事件

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。